Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs
Portfolio Pulse from Vandana Singh
Goldman Sachs has upgraded Geron Corporation (GERN) to Buy from Neutral, with a price target of $4. The FDA has assigned a standard review and a PDUFA action date of June 16, 2024, for Geron's New Drug Application for imetelstat. The FDA plans to hold an advisory committee meeting. The recent approval of Bristol-Myers Squibb & Co's Reblozyl does not negate the opportunity for imetelstat. The recent pullback in GERN shares has presented a buying opportunity.
September 12, 2023 | 6:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs has upgraded Geron Corporation to Buy from Neutral, indicating a positive outlook for the company. The FDA's standard review for Geron's new drug, imetelstat, also suggests potential growth.
The upgrade by Goldman Sachs indicates a positive outlook for Geron Corporation. The FDA's standard review for Geron's new drug, imetelstat, suggests potential growth for the company. This, combined with the recent pullback in GERN shares, presents a buying opportunity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
The recent approval of Bristol-Myers Squibb & Co's Reblozyl does not negate the opportunity for Geron's imetelstat, suggesting a neutral impact on BMY.
The recent approval of Bristol-Myers Squibb & Co's Reblozyl does not negate the opportunity for Geron's imetelstat. This suggests that the impact on BMY's stock is neutral.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50